GLP-1 pill vs injection: what actually differs

Why the milligram numbers look so different

Because they measure different things. The label swaps a 25 mg tablet for a 2.4 mg shot, and both figures are correct.

The Wegovy label prints the swap outright. A person on 2.4 mg of the injection once a week may move to 25 mg of the tablet once a day, starting a week after the last shot.

Put both on the same clock and the reason is visible. A week of tablets is 25 mg times 7 days, which is 175 mg. A week of the shot is 2.4 mg. That is about 73 times as many milligrams for what the label treats as the same step.

A swallowed tablet has to survive the stomach, so most of what is in it never reaches the blood. The number on the tablet is not a stronger dose. It is the same job counted in a different unit.

“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”

The label covering Rybelsus and Ozempic tablets opens its dosing section with that line. Two tablets of the same molecule from the same company do not share a scale either.

All three tablet ladders, day by day sets the three schedules against each other, with the strengths each one uses.

What each form asks of you

A weekly injection asks for one act a week. A daily tablet asks for a clear thirty minutes every morning, and it asks on all seven days.

The row people underestimate is the second one. Thirty minutes of nothing but water is a small ask on one morning and a routine that has to hold on all of them.

Does the form change how often the dose goes wrong?

It does, but not simply between a pill and a pen. FDA reports differ most between products people measure themselves and products that arrive premeasured.

Read the last two rows first. Those are the products drawn out of a vial with a syringe, and they are the only ones on this table with an exact figure to report.

The tablet is not better than the pen here. Both sit in the same band, and both figures are upper limits rather than measurements. A term outside a product’s 25 most-reported carries no exact count, so the study publishes a ceiling instead of a zero.

That distinction prevents an easy overstatement. What the tablet removes is the arithmetic, and the arithmetic is what separates the bottom of this table from the top.

These are shares of each product’s own reports, never rates. FDA’s data has no denominator, nobody counted the people who took either form and filed nothing, and a report is not proof the drug caused anything.

The dose-handling study behind those figures sets nine products against the device each one uses, with a control term that stays flat across all of them.

Are the two forms approved for the same things?

No, and this is the difference most likely to decide it for you. The tablet carries a shorter list than the shot it came from.

The Wegovy shot is approved for four things. Its tablet is approved for two of them, and it is a separate application rather than a second form of the same one.

Weight reduction from age 12 and liver disease are on the shot’s label only. If a prescription names either, the tablet does not cover it.

The other direction holds too. The two diabetes tablets are approved for blood sugar and not for weight, whatever the brand name on the bottle suggests.

Can you switch between them?

Yes, and the Wegovy label prints both directions with the gap to leave in between.

The two gaps are not the same length, and the reason is the drug rather than the paperwork. A weekly shot is still in the body a week later, so the label waits. A tablet is not, so the next form starts the following day.

One more line sits in the same section. Where the 25 mg tablet is not handled well, the label points at the 1.7 mg injection rather than at a smaller tablet.

Does the pill work as well as the shot?

Nothing on this site answers that, and saying so is more useful than an answer we cannot back.

No trial in these sources compares the Wegovy tablet against the Wegovy injection head to head. The two forms were approved on separate applications with separate trial programs, which is not the same thing as a comparison.

The closest thing to an official statement is the swap in the table above. A regulator agreed those two doses can follow each other. That is a dosing instruction, and it is not a claim that the outcomes match.

Anyone telling you which form works better is telling you something the labels do not.

Is there a Mounjaro or Zepbound pill?

No. There is no oral tirzepatide of any kind, so the pill-or-shot choice does not exist for those two.

FDA’s drug code directory lists what companies are shipping, and it holds no tirzepatide tablet. Both of Lilly’s tirzepatide products are injections.

Sellers online advertise a tirzepatide pill anyway. Whatever the packaging says, such a product is neither Mounjaro nor Zepbound. The page on compounded tirzepatide covers what a copy is and is not.

Is the pill here the only GLP-1 tablet?

No, and the newer one changes the timing row above. Orforglipron is a tablet with no fasting window, and there is no injection of it to weigh it against.

It reached the market on 2026-04-01 as Foundayo, approved for weight only. Its label says with or without food, so the empty stomach and the thirty clear minutes are a semaglutide rule rather than a tablet rule.

That is also why it is not a third column above. This page is about choosing between two forms of one drug, and no orforglipron injection exists to choose against. Its own dose chart carries the six strengths and the interaction ceiling.

What this comparison cannot tell you

Four things, and the first is the one people most want settled.

• No trial on this site compares the Wegovy tablet against the Wegovy injection head to head. The labels’ switching instructions are the closest thing to an official comparison and they are dosing instructions, not a result.
• Report counts are not rates. FDA’s side-effect data does not say how many people took either form without filing a report, and a report is not proof the drug caused anything.
• Cost is a separate question with a separate answer, and the two forms do not split the way people expect. It is on the price page rather than here.
• Which form a plan pays for is decided by the plan, and no public file we can read holds that answer for you.